Innoviva (INVA) EBITDA (2010 - 2026)
Innoviva posted quarterly EBITDA of $38.2 million for Q1 2026, down 7.9% year-on-year from $41.4 million in Q1 2025, and up 376.02% on a QoQ basis from -$13.8 million in Q4 2025.
Innoviva (INVA) has 17 years of EBITDA data on file, last reported at $38.2 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA fell 7.9% year-over-year to $38.2 million; the trailing twelve-month figure through Mar 2026 stood at $107.7 million (down 16.42% YoY), and the FY2025 full-year result was $163.7 million, down 1.87% from the prior year.
- EBITDA for Q1 2026 stood at $38.2 million, up from -$13.8 million in the prior quarter.
- Across five years, EBITDA topped out at $86.0 million in Q3 2023 and bottomed at -$13.8 million in Q4 2025.
- The 5-year median for EBITDA is -$6.6 million (2023), against an average of $15.1 million.
- The widest annual swing landed in 2022, when EBITDA plunged 109.55%; it then jumped 1718940.0% in 2023.
- A 5-year view of EBITDA shows it stood at -$10.3 million in 2022, then surged by 36.31% to -$6.6 million in 2023, then plunged by 60.22% to -$10.5 million in 2024, then tumbled by 31.16% to -$13.8 million in 2025, then surged by 376.02% to $38.2 million in 2026.
- The last three EBITDA figures came in at $38.2 million (Q1 2026), -$13.8 million (Q4 2025), and $34.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 38.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.15 Mn |
| Dec 31, 2025 | -13.82 Mn |
| Sep 30, 2025 | 34.58 Mn |
| Jun 30, 2025 | 48.75 Mn |
| Mar 31, 2025 | 41.43 Mn |
| Dec 31, 2024 | -10.54 Mn |
| Sep 30, 2024 | 43.24 Mn |
| Jun 30, 2024 | 54.69 Mn |
| Mar 31, 2024 | -10.23 Mn |
| Dec 31, 2023 | -6.58 Mn |
| Sep 30, 2023 | 85.95 Mn |
| Jun 30, 2023 | -9.63 Mn |
| Mar 31, 2023 | -11.35 Mn |
| Dec 31, 2022 | -10.33 Mn |
| Sep 30, 2022 | 5,000.00 |
| Jun 30, 2022 | -9.22 Mn |
| Mar 31, 2022 | -8.78 Mn |
| Dec 31, 2021 | -6.05 Mn |
| Sep 30, 2021 | 94.55 Mn |
| Jun 30, 2021 | 96.54 Mn |
| Mar 31, 2021 | -5.44 Mn |
| Dec 31, 2020 | -6.45 Mn |
| Sep 30, 2020 | 84.43 Mn |
| Jun 30, 2020 | 75.79 Mn |
| Mar 31, 2020 | 76.12 Mn |
| Dec 31, 2019 | 73.64 Mn |
| Sep 30, 2019 | 60.79 Mn |
| Jun 30, 2019 | 59.76 Mn |
| Mar 31, 2019 | 52.17 Mn |
| Dec 31, 2018 | 77.22 Mn |
| Sep 30, 2018 | 57.66 Mn |
| Jun 30, 2018 | 62.68 Mn |
| Mar 31, 2018 | 40.70 Mn |
| Dec 31, 2017 | 66.41 Mn |
| Sep 30, 2017 | 40.02 Mn |
| Jun 30, 2017 | 47.83 Mn |
| Mar 31, 2017 | 29.34 Mn |
| Dec 31, 2016 | 37.66 Mn |
| Sep 30, 2016 | 27.92 Mn |
| Jun 30, 2016 | 25.88 Mn |
| Mar 31, 2016 | 17.53 Mn |
| Dec 31, 2015 | 17.29 Mn |
| Sep 30, 2015 | 8.43 Mn |
| Jun 30, 2015 | 5.11 Mn |
| Mar 31, 2015 | 745,000.00 |
| Dec 31, 2014 | 130,000.00 |
| Sep 30, 2014 | -9.54 Mn |
| Jun 30, 2014 | -9.79 Mn |
| Mar 31, 2014 | -14.72 Mn |
| Dec 31, 2013 | -7.42 Mn |
| Sep 30, 2013 | -7.71 Mn |
| Jun 30, 2013 | -6.90 Mn |
| Mar 31, 2013 | -33.39 Mn |
| Dec 31, 2012 | -42.13 Mn |
| Sep 30, 2012 | -33.35 Mn |
| Jun 30, 2012 | -35.71 Mn |
| Mar 31, 2012 | 86.04 Mn |
| Dec 31, 2011 | -35.58 Mn |
| Sep 30, 2011 | -29.20 Mn |
| Jun 30, 2011 | -23.66 Mn |
| Mar 31, 2011 | -21.30 Mn |
| Dec 31, 2010 | -17.93 Mn |
| Sep 30, 2010 | -19.85 Mn |
| Jun 30, 2010 | -19.43 Mn |